Clinical Trials Logo

Relapsed Solid Tumors clinical trials

View clinical trials related to Relapsed Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06150365 Recruiting - Clinical trials for Refractory Solid Tumors

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Start date: November 7, 2023
Phase: Early Phase 1
Study type: Interventional

This trial is a single arm, open phase I clinical study to investigate the safety and efficacy of personalized KSX01-TCRT in patients with advanced solid tumors. This experiment is divided into two parts: the dose increasing stage (Part A) and the dose expanding stage (Part B). For those enrolled in the planned expansion phase, the dose should have passed the safety assessment during the dose escalation phase.

NCT ID: NCT05811975 Recruiting - Clinical trials for Refractory Solid Tumors

KSX01-TCRT Injection Project in Solid Tumors

Start date: March 7, 2023
Phase: Early Phase 1
Study type: Interventional

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

NCT ID: NCT05539833 Recruiting - Clinical trials for Refractory Solid Tumors

KSH01-TCRT Solid Tumors

KSH01-TCRT
Start date: August 19, 2022
Phase: Early Phase 1
Study type: Interventional

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

NCT ID: NCT04718675 Recruiting - Clinical trials for Non-Hodgkin Lymphoma

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Start date: February 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL). Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts.